Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 9k
25 January 2021
E-000424/2021
Question for written answer  E-000424/2021
to the Commission
Rule 138
Stefania Zambelli (ID)
 Answer in writing 
 Subject: Delays in COVID-19 vaccine rollout

The news regarding significant reductions in supplies of COVID-19 vaccines by Pfizer and also by AstraZeneca, which is due to receive EMA marketing authorisation next week, is giving rise to widespread concern.

The vaccination programme has been suspended in several regions of Italy as a result.

In view of this:

1. What action will the Commission take regarding those responsible for breach of contract through reduced supplies of vaccine?

2. What measures will it take to verify claims by the pharmaceutical companies that the reduction in supply is due to production problems or establish whether other factors may be at play?

3. What action will it take should it be discovered that the undelivered doses of vaccine have in fact been sold outside the EU under different contractual terms?

Original language of question: IT
Last updated: 11 February 2021Legal notice - Privacy policy